Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A method for directly secreting and expressing mature double-chain insulin glargine by using Saccharomyces cerevisiae

A technology of insulin glargine and Saccharomyces cerevisiae, which is applied in the field of protein drug production and can solve the problems of wasting carbon source raw materials and biological enzyme preparations, etc.

Active Publication Date: 2021-08-03
SUN YAT SEN UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the use of Saccharomyces cerevisiae still fails to avoid enzyme digestion in vitro and the formation of a large number of by-products, which wastes carbon raw materials and biological enzyme preparations, which is not an exquisite and efficient production method

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A method for directly secreting and expressing mature double-chain insulin glargine by using Saccharomyces cerevisiae
  • A method for directly secreting and expressing mature double-chain insulin glargine by using Saccharomyces cerevisiae
  • A method for directly secreting and expressing mature double-chain insulin glargine by using Saccharomyces cerevisiae

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0062] Example 1 Construction of Kex2 protease recombinant expression system

[0063] The overall objective of the present invention is to directly synthesize and secrete mature insulin glargine from Saccharomyces cerevisiae cells. Among them, the intracellular enzyme cleavage of proinsulin glargine to form a double-chain structure must first be realized. In the molecular structure of insulin glargine, the end of the B chain contains a structure of double basic amino acids Arg-Arg, which can be recognized and cut by Kex2. Therefore, the way to achieve insulin cleavage can be the endogenous Kex2 naturally present in yeast. However, due to the insufficient expression of endogenous Kex2 in Saccharomyces cerevisiae cells, the cleavage of its own alpha factor is still incomplete. Therefore, in order to achieve recombinant expression of insulin glargine in Saccharomyces cerevisiae, it is necessary to co-express a higher level and higher efficiency of Kex2 to complete sufficient cu...

Embodiment 2

[0109] The direct synthesis and secretion of embodiment 2 insulin glargine

[0110] In this example, on the basis of the research in Example 1, the No. 4 strain constructed in Example 1 was selected. According to the same method, the fragment MBP-linker-eGFP in the recombinant plasmid pYES2-alpha-MBP-linker-eGFP The co-expression system of insulin glargine and Kex2 was constructed by replacing it with the optimized insulin glargine sequence (as shown in SEQ ID NO.3). The expressed protein was then immunologically characterized by ELISA, and it was confirmed that the co-expressed insulin was cleaved by Kex2. After purification by cation exchange chromatography, the molecular weight of the expressed protein was verified by MALDI-TOF, and its peptide fingerprint was further determined, and its disulfide bond position and Kex2 cleavage position were verified. In addition, the retention time was verified by liquid chromatography-mass spectrometry, and the amino acid sequence was d...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a method for directly secreting and expressing mature double-chain insulin glargine using Saccharomyces cerevisiae. This method first constructs chassis cells that overexpress Kex2, and then transfers the tandem signal peptide and codon-optimized insulin glargine DNA into the chassis cells that overexpress Kex2 to form a Saccharomyces cerevisiae co-expression system, and performs protein expression and purification to obtain Insulin glargine. This method greatly reduces the difficulty of the insulin glargine production process, simplifies the tedious and complex multi-step downstream processing of the traditional process, and allows yeast cells to directly complete the modification work within the cell. At the same time, this method reduces the complexity of purification and can directly extract mature insulin protein from the culture medium through one-step, relatively low-cost ion exchange purification. In addition, by avoiding the use of ingredients such as trypsin, nearly 50% of the by-products in the original process are avoided, which improves the fermentation efficiency of carbon sources and other nutrients in the culture medium, and has good prospects for promotion and application.

Description

technical field [0001] The invention belongs to the technical field of protein medicine production. More specifically, it relates to a method for directly secreting and expressing mature double-chain insulin glargine by using Saccharomyces cerevisiae. Background technique [0002] Diabetes is a chronic disease with high incidence in today's society. Insulin products are the largest drug category in the diabetes market, accounting for about 53% of the market share, of which third-generation recombinant insulin is the main product. Insulin glargine belongs to the third generation of recombinant insulin. It is a long-acting insulin with no obvious peak and the risk of hypoglycemia and sudden death. Due to its safety and long-acting characteristics, insulin glargine Lantus has continued to become The product with the largest market share in the insulin market, accounting for more than 30% of the overall insulin market. [0003] Most of the existing insulin glargine production...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N15/81C12N15/62C12N1/19C12R1/865
CPCC07K14/62C07K2319/02C07K2319/21C12N9/60C12N15/62C12N15/81
Inventor 阿迪亚陆勇军
Owner SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com